Skip to main content
. 2024 Nov 3;15:20406207241292508. doi: 10.1177/20406207241292508

Figure 3.

Figure 3.

Annualized rate of VOCs leading to healthcare visit by each year in the crizanlizumab 5.0 and 7.5 mg/kg groups.

The whiskers are minimum and maximum, the boxes are interquartile ranges, and horizontal lines and displayed values in the boxes are medians. VOC, vaso-occlusive crisis.